FedEx's Upcoming Earnings: Navigating Headwinds to Unlock Logistics Growth

The logistics sector faces a perfect storm of inflationary pressures, contracting B2B volumes, and expiring contracts, yet FedEx (FDX) remains a paradox: a company with near-term challenges but long-term strategic assets that could position it as an undervalued growth story. As the company prepares for its June 24 earnings report—tentatively set to reveal fourth-quarter results—investors must parse whether FedEx's structural advantages outweigh its current struggles. The answer hinges on its ability to execute on cost savings, healthcare expansion, and network modernization while navigating an uncertain economy.

The Q3 Performance: Progress Amid Caution

FedEx's third-quarter results, reported in March, showed resilience in core metrics but also vulnerability. Revenue grew 2% year-over-year, the first such growth this fiscal year, driven by Federal Express volume increases. Adjusted operating income rose 12%, with Federal Express contributing a robust 17% gain. Cost discipline shone through: the $600 million DRIVE savings in Q3 brought the year-to-date total to $1.4 billion, edging closer to its $2.2 billion annual target. Yet the stock fell 6.45% post-report as FedEx lowered its full-year EPS guidance to $18–$18.60 from a prior $19.50–$20.50 range. The culprit? The expiration of the U.S. Postal Service contract, inflation, and a sluggish industrial sector denting higher-margin B2B shipments.

Q4 Earnings: A Litmus Test for Resilience

Analysts now eye Q4 with heightened scrutiny. The consensus EPS forecast of $5.88—a 8.7% rise from last year's $5.41—rests on hopes that FedEx can stabilize its B2B business and leverage its healthcare vertical. FedEx's stock price performance around recent earnings releases has historically been volatile, but this report's significance extends beyond quarterly figures. Investors will monitor:
- Whether the company meets its lowered FY25 EPS guidance.
- Progress toward $9 billion in healthcare revenue, up from $7.5 billion in FY23.
- Cost-saving momentum, as DRIVE savings must reach $2.2 billion by year-end.

Backtest the performance of FedEx (FDX) when buying 1 day before quarterly earnings announcements and holding for 20 trading days, from 2020 to 2025.

The Undervalued Growth Case: Where the Market Might Be Missing

FedEx's stock trades at 14.7x the midpoint of its revised FY25 EPS guidance, below its five-year average of 16.3x. This discounts its strategic advantages:

1. Healthcare's Quiet Revolution
FedEx's healthcare segment—targeting $9 billion in revenue—leverages its cold-chain logistics and pharmaceutical expertise. While underappreciated by traders focused on macroeconomic noise, this business offers stable, high-margin growth.

.

2. Network 2.0 and RouteSmart's Efficiency Play
The $4.9 billion CapEx budget is funding "Network 2.0," a reorganization to reduce costs and improve speed, while the RouteSmart acquisition optimizes delivery routes. These initiatives aim to cut $2 billion in annual costs by 2026. If realized, they could fuel margin expansion even in a slow economy.

3. Shareholder Returns Amid Caution
Despite headwinds, FedEx plans to return $3.8 billion to shareholders via dividends and buybacks. This signals confidence in cash flow stability, even as it scales back guidance.

Risks and the Bear Case

The market's skepticism isn't unwarranted. The USPS contract expiration alone costs $200–$300 million annually, and B2B demand could remain weak if the industrial sector falters. Inflation pressures also linger, squeezing margins.

Investment Thesis: A Buy on Dip Ahead of Q4

FedEx's stock has underperformed peers like UPS (UPS) by 12% year-to-date, despite comparable revenue trajectories. . The disconnect suggests a buying opportunity if Q4 results beat lowered expectations. Key catalysts include:
- Healthcare revenue exceeding $8.5 billion for the year.
- DRIVE savings hitting the $2.2 billion target.
- Federal Express volumes stabilizing.

Conclusion: A Logistics Leader in Disguise

FedEx's valuation gap reflects near-term macro risks, but its structural advantages—healthcare dominance, network modernization, and disciplined cost-cutting—position it to outperform as the economy stabilizes. Investors willing to look beyond the next quarter may find a compelling entry point ahead of the June 24 report. For those focused on undervalued growth stories, FedEx's mix of resilience and innovation makes it a stock to watch closely in this uncertain landscape.

Recommendation: Consider a gradual accumulation of shares at current levels, with a 12-month target of $180–$190 (implied 16–17x FY25 EPS), contingent on Q4 execution. Monitor the healthcare segment's progress closely—it could be the key to unlocking this undervalued logistics giant's potential.